Growth Hormone (GH) Replacement Therapy Decreased Plasma Diacron-reactive Oxygen Metabolites levels and subsequently, improved Endothelial Function as Assessed by Peripheral Arterial Tonometry in Japanese Patient with growth Hormone deficiency

Growth Hormone (GH) Replacement Therapy Decreased Plasma Diacron-reactive Oxygen Metabolites levels and subsequently, improved Endothelial Function as Assessed by Peripheral Arterial Tonometry in Japanese Patient with growth Hormone deficiency - The effect of GH replacement therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025223

Enrollment

Registered

2017-02-01

Start date

2017-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Hormone Deficiency

Interventions

Patients with GH dificiency who unreceived GH replacement therapy were enrolled. Endothelial function by reactive hyperaemia index(RHI

EndoPAT system), d-ROMS, blood pressure, fasting lipids. Plasma GH levels and insulin-like growth factor -1 were also measured at baseline and following GH replacement after 24 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: GH deficient hypopituitary subjects

Exclusion criteria

Exclusion criteria: 1.type 1 or 2 diabetes, 2.severe liver dysfunction 3.severe infections 4.pregnant or nursing women and those who might be pregnant 5.malignancy or the history of malignancy 6.alcoholism 7 any patients whom the investigators judged to be inappropriate for this study.

Design outcomes

Primary

Measure	Time frame
The changes in endothelial function and oxidative stress after GH replacement therapy	—

Countries

Japan

Contacts

Public ContactChie Aoki

Dokkyo Medical University Endocrinology and Metabolism

c-aoki@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026